Evidence map›Paper›PMID 27465783›Full record

ArticleBMC infectious diseases2016

Where there is hope: a qualitative study examining patients' adherence to multi-drug resistant tuberculosis treatment in Karakalpakstan, Uzbekistan.

Shona Horter, Beverley Stringer, Jane Greig, Akhmet Amangeldiev, Mirzagaleb N Tillashaikhov, Nargiza Parpieva, Zinaida Tigay, Philipp du Cros

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Treatment Adherence With an Oral 9-Month Regimen for Rifampicin-Resistant Tuberculosis in South Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Observational
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Shona HorterMédecins Sans Frontières (UK), Lower Ground Floor, Chancery Exchange, 10 Furnival Street, London, EC4A 1AB, UK. shona_horter@yahoo.co.uk.
Beverley StringerMédecins Sans Frontières (UK), Lower Ground Floor, Chancery Exchange, 10 Furnival Street, London, EC4A 1AB, UK.
Jane GreigMédecins Sans Frontières (UK), Lower Ground Floor, Chancery Exchange, 10 Furnival Street, London, EC4A 1AB, UK.
Akhmet AmangeldievMSF, Nukus, Uzbekistan.
Mirzagaleb N TillashaikhovMinistry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.
Nargiza ParpievaMinistry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan.
Zinaida TigayTB II Hospital, Nukus, Uzbekistan.
Philipp du CrosMédecins Sans Frontières (UK), Lower Ground Floor, Chancery Exchange, 10 Furnival Street, London, EC4A 1AB, UK.
Médecins Sans Frontières‎ · GBMinistry of Health of the Republic of Uzbekistan · UZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTreatment for multi-drug resistant tuberculosis (MDR-TB) is lengthy, has severe side effects, and raises adherence challenges. In the Médecins Sans Frontières (MSF) and Ministry of Health (MoH) programme in Karakalpakstan, Uzbekistan, a region with a high burden of MDR-TB, patient loss from treatment (LFT) remains high despite adherence support strategies. While certain factors associated with LFT have been identified, there is limited understanding of why some patients are able to adhere to treatment while others are not. We conducted a qualitative study to explore patients' experiences with MDR-TB treatment, with the aim of providing insight into the barriers and enablers to treatment-taking to inform future strategies of adherence support.

methodsParticipants were purposively selected. Programme data were analysed to enable stratification of patients by adherence category, gender, and age. 52 in-depth interviews were conducted with MDR-TB patients (n = 35) and health practitioners (n = 12; MSF and MoH doctors, nurses, and counsellors), including five follow-up interviews. Interview notes, then transcripts, were analysed using coding to identify emerging patterns and themes. Manual analysis drew upon principles of grounded theory with constant comparison of codes and categories within and between cases to actively seek discrepancies and generate concepts from participant accounts. Ethics approval was received from the MoH of the Republic of Uzbekistan Ethics Committee and MSF Ethics Review Board.

resultsSeveral factors influenced adherence. Hope and high quality knowledge supported adherence; autonomy and control enabled optimal engagement with treatment-taking; and perceptions of the body, self, treatment, and disease influenced drug tolerance. As far as we are aware, the influence of patient autonomy and control on MDR-TB treatment-taking has not previously been described. In particular, the autonomy of married women around treatment-taking was potentially undermined through their societal position as daughter-in-law, compromising their ability to adhere to treatment. Patients' engagement with and adherence to treatment could be hindered by hierarchical practitioner-patient relationships that displaced authority, ownership, and responsibility from the patient.

conclusionsOur findings reinforce the need for an individualised and holistic approach to adherence support with engagement of patients as active participants in their care who feel ownership and responsibility for their treatment.

Indexed as

AdolescentAdultAgedAntitubercular AgentsAttitude to HealthFemaleHopeHumansMaleMiddle AgedPatient CompliancePersonal AutonomyQualitative ResearchSelf ConceptTuberculosis, Multidrug-ResistantUzbekistanAntitubercular AgentsAdherenceAutonomyDrugsMDR-TBMulti-drug resistant tuberculosisQualitative studySide effects

Identifiers

PMID27465783
PMCPMC4964095
OpenAlexW2490811060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.